DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
GDC-0349 is an investigational drug.
There have been 169 clinical trials for GDC-0349. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2010.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lymphoma. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.
Recent Clinical Trials for GDC-0349
|A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of GDC-9545 Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer||Hoffmann-La Roche||Phase 2|
|Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN||National Cancer Institute (NCI)||Phase 1/Phase 2|
|Evaluation of the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Females of Non-Childbearing Potential||Genentech, Inc.||Phase 1|